FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W173767460> ?p ?o ?g. }

• W173767460 endingPage "6" @default.
• W173767460 startingPage "2281" @default.
• W173767460 abstract "Recent studies have shown that angiogenesis, which is induced by VEGF, may be involved in the pathogenesis of hematopoietic malignancies. A human leukemia model consisting of T-lymphoblastic CEM/0, 7 monoclonal refractory clones resistant to both cytosine arabinoside (ara-C) and L-asparaginase (ASNase), Jurkat/E6-1 and U937, representing the leukemic blasts from relapsed patients with leukemias was investigated for secretion of VEGF before and after treatment with various agents. The T-lymphoblastic cell line, Jurkat/E6-1, was used as the negative control, which has been characterized as not expressing mRNA nor the VEGF protein, and did not secrete VEGF. With no treatment, U937, the positive control, secreted the highest VEGF concentration of 1612.7 pg/ml. The CEM/O wild type cell line and 5 other drug-resistant clones secreted VEGF at levels ranging from 180.9 to 414.2 pg/ml. Two CEM drug-resistant clones, CEM/ara-C/G/ASNase-0.5-1 and CEM/ara-C/G/ASNase-1-1, lacked VEGF production. Docetaxel (Taxotere, TXR), Vincristine (VCR), ASNase, and the Fit-1/Fc chimera, a specific inhibitor of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, were tested for inhibition of VEGF secretion. Treatment of the leukemic cell lines with 2 microg/ml Flt-1/Fc chimera for 24 hours completely inhibited VEGF secretion to the detection limit of the assay (<10pg/ml). After 24 hours incubation with Flt-1/Fc chimera, the leukemic cells appeared to be undergoing apoptosis, based on microphotography examination, suggesting that VEGF could be used in an autocrine loop to promote cell survival by the leukemic cells. Treatment with 0.5, 1, and 2 microg/ml Flt-1/FC chimera for 48 hours demonstrated a 15-25% growth inhibition by MTT assay. Strong inhibition of VEGF secretion in the culture media was observed after 10 microM TXR or 0.1 microM VCR for 24 hours in the wild-type and drug-resistant clones, except CEM/ara-C/I, in comparison with controls. In contrast, treatment with 1 IU/ml ASNase, a specific T-cell protein inhibitor, in 5 cell lines for 24 hours demonstrated no inhibition of VEGF in CEM/0 3 drug-resistant clones and the myeloid U937 line. We conclude that the leukemia cell lines actively secrete VEGF, in vitro. TXR and VCR, but not ASNase, strongly inhibit the VEGF production, suggesting that inhibition of this growth factor may be a mechanism of antileukemic activity. Moreover, the leukemic cell lines examined here may constitute a useful model to study antiangiogenic drugs, alone or in combination with established drug regimens used against refractory leukemias." @default.
• W173767460 created "2016-06-24" @default.
• W173767460 creator A5006509781 @default.
• W173767460 creator A5025288612 @default.
• W173767460 creator A5056302309 @default.
• W173767460 date "2001-11-29" @default.
• W173767460 modified "2023-09-23" @default.
• W173767460 title "Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines." @default.
• W173767460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11724283" @default.
• W173767460 hasPublicationYear "2001" @default.
• W173767460 type Work @default.
• W173767460 sameAs 173767460 @default.
• W173767460 citedByCount "27" @default.
• W173767460 countsByYear W1737674602012 @default.
• W173767460 countsByYear W1737674602015 @default.
• W173767460 countsByYear W1737674602016 @default.
• W173767460 countsByYear W1737674602017 @default.
• W173767460 countsByYear W1737674602018 @default.
• W173767460 countsByYear W1737674602019 @default.
• W173767460 countsByYear W1737674602020 @default.
• W173767460 countsByYear W1737674602022 @default.
• W173767460 crossrefType "journal-article" @default.
• W173767460 hasAuthorship W173767460A5006509781 @default.
• W173767460 hasAuthorship W173767460A5025288612 @default.
• W173767460 hasAuthorship W173767460A5056302309 @default.
• W173767460 hasConcept C126322002 @default.
• W173767460 hasConcept C134018914 @default.
• W173767460 hasConcept C153911025 @default.
• W173767460 hasConcept C167734588 @default.
• W173767460 hasConcept C179464577 @default.
• W173767460 hasConcept C203014093 @default.
• W173767460 hasConcept C2776090121 @default.
• W173767460 hasConcept C2776694085 @default.
• W173767460 hasConcept C2776755627 @default.
• W173767460 hasConcept C2777025900 @default.
• W173767460 hasConcept C2778461978 @default.
• W173767460 hasConcept C2779429289 @default.
• W173767460 hasConcept C2780394083 @default.
• W173767460 hasConcept C49039625 @default.
• W173767460 hasConcept C502942594 @default.
• W173767460 hasConcept C54355233 @default.
• W173767460 hasConcept C71924100 @default.
• W173767460 hasConcept C81885089 @default.
• W173767460 hasConcept C86803240 @default.
• W173767460 hasConcept C8891405 @default.
• W173767460 hasConceptScore W173767460C126322002 @default.
• W173767460 hasConceptScore W173767460C134018914 @default.
• W173767460 hasConceptScore W173767460C153911025 @default.
• W173767460 hasConceptScore W173767460C167734588 @default.
• W173767460 hasConceptScore W173767460C179464577 @default.
• W173767460 hasConceptScore W173767460C203014093 @default.
• W173767460 hasConceptScore W173767460C2776090121 @default.
• W173767460 hasConceptScore W173767460C2776694085 @default.
• W173767460 hasConceptScore W173767460C2776755627 @default.
• W173767460 hasConceptScore W173767460C2777025900 @default.
• W173767460 hasConceptScore W173767460C2778461978 @default.
• W173767460 hasConceptScore W173767460C2779429289 @default.
• W173767460 hasConceptScore W173767460C2780394083 @default.
• W173767460 hasConceptScore W173767460C49039625 @default.
• W173767460 hasConceptScore W173767460C502942594 @default.
• W173767460 hasConceptScore W173767460C54355233 @default.
• W173767460 hasConceptScore W173767460C71924100 @default.
• W173767460 hasConceptScore W173767460C81885089 @default.
• W173767460 hasConceptScore W173767460C86803240 @default.
• W173767460 hasConceptScore W173767460C8891405 @default.
• W173767460 hasIssue "4A" @default.
• W173767460 hasLocation W1737674601 @default.
• W173767460 hasOpenAccess W173767460 @default.
• W173767460 hasPrimaryLocation W1737674601 @default.
• W173767460 hasRelatedWork W169912869 @default.
• W173767460 hasRelatedWork W1860600423 @default.
• W173767460 hasRelatedWork W2083817342 @default.
• W173767460 hasRelatedWork W2150529368 @default.
• W173767460 hasRelatedWork W2160222685 @default.
• W173767460 hasRelatedWork W2361507206 @default.
• W173767460 hasRelatedWork W2393310753 @default.
• W173767460 hasRelatedWork W2439153654 @default.
• W173767460 hasRelatedWork W24668930 @default.
• W173767460 hasRelatedWork W4239247100 @default.
• W173767460 hasVolume "21" @default.
• W173767460 isParatext "false" @default.
• W173767460 isRetracted "false" @default.
• W173767460 magId "173767460" @default.
• W173767460 workType "article" @default.